Park Medi World IPO FY2025 – The ₹920 Crore Healthcare Hustle With Hospital Beds, Borrowings, and Big Ambitions
1. At a Glance
Park Medi World Ltd — the hospital chain that wants to cure your ailments and your portfolio boredom — has rolled out a blockbuster ₹920 crore IPO. The offer is a split prescription: ₹770 crore fresh issue (new shares, new money) and ₹150 crore offer for sale (old shareholders cashing out a bit). Price band? ₹154–₹162 per share. The lot size? 92 shares — small enough for retail and large enough to feel like you’re buying your own hospital bed.
With a pre-IPO market cap of ₹6,997 crore and post-issue valuation brushing ₹7,000+ crore, Park Medi World wants to join the league of India’s elite hospital chains. Its pre-issue P/E sits around 29.2x, easing to 25.1x post-issue — not cheap, but hey, who said healthcare was ever cheap?
And the growth story? Between FY24 and FY25, revenue rose 13%, while profit after tax jumped 40%. Yes, margins widened, patients multiplied, and debt remained in check at a 0.61x debt-to-equity ratio. So, is this IPO a cure for your FOMO or just another dose of overvaluation fever? Let’s diagnose it together.
2. Introduction
Once upon a sterile corridor in North India, Park Medi World decided that “scaling up” wasn’t just for Excel sheets — it was for hospital beds too. From one modest hospital to 14 multi-super-speciality fortresses across Delhi, Haryana, Punjab, and Rajasthan, this healthcare chain now claims over 3,000 beds, 67 OTs, and an oxygen plant in every location. Because, you know, after 2020, not having your own oxygen supply is basically like a restaurant running without a kitchen.
Founded in 2011 by Dr. Ajit Gupta and Dr. Ankit Gupta, Park Medi World runs the “Park Hospitals” brand — where NABH and NABL accreditations are badges of hygiene honor. Their recipe for expansion is classic desi corporate medicine: buy stressed hospitals cheap, inject efficiency, cut costs, and within a year — boom! — they start showing up in the profit columns.
The ₹920 crore IPO is their financial stethoscope into the capital markets. The proceeds will partly repay ₹380 crore of debt, fund expansion and new equipment, and save a slice for future acquisitions. Think of it as a balance between curing old loans and opening new wings. But beneath the shiny NABH certificates and ICUs, what do the numbers say? And more importantly — is this healthcare empire robust enough to handle investor blood pressure?
3. Business Model – WTF Do They Even Do?
Park Medi World isn’t your neighborhood clinic — it’s a doctor-led empire of private hospitals, each fighting for your health and your wallet. Their business model runs on three key arteries:
1. Hospital Operations (Core): This is where the magic happens — revenue from patient services, surgeries, and diagnostics. They offer 30+ specialties: internal medicine, neurology, gastroenterology, oncology, orthopaedics, and urology. Basically, everything from fixing your bones to billing your insurance.
2. Medical Equipment and Facility Expansion: They’re actively upgrading facilities, adding beds, ICU capacity, and equipment. Oxygen generation plants at every hospital signal strong operational foresight — no dependence on external suppliers during crises.
3. Strategic Acquisitions: Park Medi World has mastered the art of buying underperforming hospitals and turning them around. Like a corporate version of Doctor Strange, they heal both patients and sick balance sheets.
Their payor mix is diverse — individual patients, insurance, and government schemes — ensuring revenue isn’t tied to a single artery. And with 1,014 doctors and 2,142 nurses as of September 2025, it’s safe to say payroll must look like a government budget line item.
So, the business model is fairly simple: acquire, upgrade, operate efficiently, and expand. Rinse, repeat, and bill.
4. Financials Overview
Let’s dissect their financials — scalpel, please.
Source table
Metric
Latest Period (Sep 2025)
YoY (Mar 2025)
Prev Year (Mar 2024)
YoY %
QoQ %
Revenue (₹ Cr)
823.39 (H1FY26 annualized ~₹1,646.8)
1,425.97
1,263.08
+13%
—
EBITDA (₹ Cr)
217.14 (annualized ~₹434.3)
372.17
310.30
+20%
—
PAT (₹ Cr)
139.14 (annualized ~₹278.3)
213.22
152.01
+40%
—
EPS (₹)
3.22 (H1FY26)
5.55 (FY25)
4.00 (FY24)
+39%
—
Commentary: The numbers scream “scalpel-sharp execution.” Revenue up 13%, PAT up 40% — looks like management’s cost-cutting surgeries have been successful. EBITDA margin at ~26.7% and PAT margin at 15.3% show they’re running a lean operation — not a charity ward. Debt remains moderate, while net worth jumped from ₹816 crore in FY24 to ₹1,153 crore by Sep 2025 — that’s a healthy transfusion of capital.
5. Valuation Discussion – Fair Value Range Only
Now let’s crunch the valuation pill:
1. P/E Method:
Post-issue EPS = ₹6.44
Price Band = ₹154–₹162 → P/E = 23.9x – 25.1x
For context, peers like Apollo Hospitals (~60x) and Narayana Hrudayalaya
